Perrigo Company plc (NYSE; TASE: PRGO) today announced it has received final approval from the U.S. Food and Drug Administration for its AB rated Abbreviated New Drug Application referencing AbbVie Inc.'s Androgel® Topical Gel, 1.62% packets (20.25 mg/1.25 g packet and 40.5 mg/2.5 g packet)...